Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Combined With Venetoclax for MRD Persisting AML
NCT07264010Phase 3Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of sorafenib, venetoclax in acute myeloid leukemia (AML), sponsored by Nanfang Hospital, Southern Medical University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sorafenibvenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07264010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264010.